NDAORALCAPSULE
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
NUPLAZID (pimavanserin tartrate) by Acadia Pharmaceuticals is unclear. First approved in 2018.
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUPLAZID (pimavanserin tartrate) is an oral small-molecule antipsychotic approved in 2018 that works primarily through inverse agonism and antagonism at serotonin 5-HT2A receptors, with secondary activity at 5-HT2C receptors. The mechanism of action remains incompletely understood but appears distinct from traditional dopamine-blocking antipsychotics. It is indicated for psychosis associated with Parkinson's disease.
Peak12.7 years to LOE
Product is in peak commercial phase with Acadia Pharmaceuticals, suggesting stable team size and mature marketing infrastructure focused on physician awareness and patient access optimization.
Mechanism of Action
unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NUPLAZID careers are concentrated in commercial and medical affairs functions within Acadia Pharmaceuticals, a specialized neurology-focused company. Roles emphasize specialist physician engagement, patient identification, and payer navigation in a niche but high-value indication with limited but concentrated patient populations.
Brand Manager
Worked on NUPLAZID at Acadia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.